269 related articles for article (PubMed ID: 15754001)
1. Antisense-thioredoxin inhibits angiogenesis via pVHL-mediated hypoxia-inducible factor-1alpha degradation.
Kim WJ; Cho H; Lee SW; Kim YJ; Kim KW
Int J Oncol; 2005 Apr; 26(4):1049-52. PubMed ID: 15754001
[TBL] [Abstract][Full Text] [Related]
2. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.
Welsh SJ; Bellamy WT; Briehl MM; Powis G
Cancer Res; 2002 Sep; 62(17):5089-95. PubMed ID: 12208766
[TBL] [Abstract][Full Text] [Related]
3. Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha.
Sun X; Kanwar JR; Leung E; Vale M; Krissansen GW
Gene Ther; 2003 Dec; 10(25):2081-9. PubMed ID: 14595381
[TBL] [Abstract][Full Text] [Related]
4. Tid-1 interacts with the von Hippel-Lindau protein and modulates angiogenesis by destabilization of HIF-1alpha.
Bae MK; Jeong JW; Kim SH; Kim SY; Kang HJ; Kim DM; Bae SK; Yun I; Trentin GA; Rozakis-Adcock M; Kim KW
Cancer Res; 2005 Apr; 65(7):2520-5. PubMed ID: 15805242
[TBL] [Abstract][Full Text] [Related]
5. von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis.
Jones MK; Szabó IL; Kawanaka H; Husain SS; Tarnawski AS
FASEB J; 2002 Feb; 16(2):264-6. PubMed ID: 11772947
[TBL] [Abstract][Full Text] [Related]
6. The role of von Hippel-Lindau protein in the differentiation of neural progenitor cells under normoxic and anoxic conditions.
Tanaka Y; Kanno H; Dezawa M; Mimura T; Kubo A; Yamamoto I
Neurosci Lett; 2005 Jul 22-29; 383(1-2):28-32. PubMed ID: 15936507
[TBL] [Abstract][Full Text] [Related]
7. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
9. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Beppu K; Nakamura K; Linehan WM; Rapisarda A; Thiele CJ
Cancer Res; 2005 Jun; 65(11):4775-81. PubMed ID: 15930297
[TBL] [Abstract][Full Text] [Related]
10. Activation of hypoxia-induced transcription in normoxia.
Hägg M; Wennström S
Exp Cell Res; 2005 May; 306(1):180-91. PubMed ID: 15878343
[TBL] [Abstract][Full Text] [Related]
11. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.
Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
EMBO J; 2003 Apr; 22(8):1857-67. PubMed ID: 12682018
[TBL] [Abstract][Full Text] [Related]
12. [Effect of silencing HIF-1alpha by RNA interference on expression of vascular endothelial growth factor in osteosarcoma cell line SaOS-2 under hypoxia].
Wu Q; Yang SH; Wang RY; Ye SN; Xia T; Ma DZ
Ai Zheng; 2005 May; 24(5):531-5. PubMed ID: 15890092
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway.
Yoo YG; Oh SH; Park ES; Cho H; Lee N; Park H; Kim DK; Yu DY; Seong JK; Lee MO
J Biol Chem; 2003 Oct; 278(40):39076-84. PubMed ID: 12855680
[TBL] [Abstract][Full Text] [Related]
15. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
16. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
17. Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells.
Alqawi O; Moghaddas M; Singh G
Prostate Cancer Prostatic Dis; 2006; 9(2):126-35. PubMed ID: 16432534
[TBL] [Abstract][Full Text] [Related]
18. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
19. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
20. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.
Chang CC; Lin MT; Lin BR; Jeng YM; Chen ST; Chu CY; Chen RJ; Chang KJ; Yang PC; Kuo ML
J Natl Cancer Inst; 2006 Jul; 98(14):984-95. PubMed ID: 16849681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
